Patents by Inventor Wentian Yang

Wentian Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11442065
    Abstract: The invention provides that OSTERIX (a.k.a. SP7) is a marker for gastrointestinal stem cells and that OSTERIX is expressed widely and at elevated levels in human gastrointestinal tumors.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: September 13, 2022
    Assignee: Rhode Island Hospital
    Inventors: Wentian Yang, Lijun Wang, Douglas C. Moore
  • Publication number: 20200378974
    Abstract: The invention provides that OSTERIX (a.k.a. SP7) is a marker for gastrointestinal stem cells and that OSTERIX is expressed widely and at elevated levels in human gastrointestinal tumors.
    Type: Application
    Filed: March 30, 2020
    Publication date: December 3, 2020
    Inventors: Wentian Yang, Lijun Wang, Douglas C. Moore
  • Patent number: 10677799
    Abstract: Ctsk is used as a marker to identify, track, and manipulate Ctsk positive cartilaginous stem cells for cartilage repair and regeneration in vitro and in vivo.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 9, 2020
    Assignee: Rhode Island Hospital
    Inventors: Wentian Yang, Nikhil Thakur
  • Patent number: 9833446
    Abstract: A method for preventing, slowing, or blocking the formation of an exostosis or an enchondromas comprising administering to an animal in need thereof a hedgehog pathway inhibitor such as a Smoothened inhibitor.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 5, 2017
    Assignees: Rhode Island Hospital, University Health Network
    Inventors: Wentian Yang, Benjamin G. Neel
  • Publication number: 20150352131
    Abstract: This application discloses compositions, devices, and methods for the prevention and treatment of osteolysis and osteoporosis. Treatment or prevention of osteolysis or osteoporosis is carried out by targeting the enzyme, Shp2 (a Src homology 2 (SH2) domain containing non-transmembrane Protein Tyrosine Phosphatase (PTP)), or proteins involved in the Shp2 signaling pathway by administering a Shp2 pathway inhibitor that inhibits fusion of pre-osteoclasts.
    Type: Application
    Filed: January 16, 2014
    Publication date: December 10, 2015
    Applicant: RHODE ISLAND HOSPITAL
    Inventors: Wentian Yang, Michael G. Ehrlich, Yi Zhou, Douglas Moore
  • Publication number: 20150045363
    Abstract: Hedgehog pathway inhibitors, such as small molecules, are used to prevent, slow, block the formation of cartilage tumors as well as exostosis or enchondromas.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Inventors: Wentian Yang, Benjamin G. Neel